Abstract 1076: Targeting EGFR and PI3K pathways with KRASG12D inhibitor overcomes oncogenic dependence in pancreatic cancer

Prashant Kashinath Bhavar,Uday Kumar Surampudi,Adilakshmi Gandham,Partha Pratim Sarma

DOI: https://doi.org/10.1158/1538-7445.am2023-1076

IF: 11.2

2023-04-04

Cancer Research

Abstract:Abstract In the U.S., pancreatic cancer is 9th most commonly diagnosed cancer (depending on gender), but the fourth leading cause of cancer death in men and women. FOLFIRINOX or gemcitabine plus nab-paclitaxel have been the standard of care for pancreatic cancer, but late stage prognosis often leads to disease progression of disease, with an overall 5 year survival of 11.5%, in the US, and 9% in Japan. KRASG12D mutant isoform is found in 36% of pancreatic adenocarcinoma patients and hence targeting this major mutation that appear early in the disease may help overcome cancer progression. Several signaling pathways are known to converge on the MAPK and PI3K pathways as effectors of cellular response within the cell. Pancreatic cancer is driven by activating mutations in KRAS, which in turn is expected to activate PI3K signalling through the p110α subunit, indicating that a large proportion of patients could benefit from effective targeting of this pathway. Role of EGFR on the other hand in KRAS-dependent pancreatic cancer progression is not well understood, and cetuximab as single agent has not provided benefit in PDAC patients. Recent studies of KRASG12C inhibitors in combination with EGFR inhibitors have shown clinical benefit in colorectal cancer possibly due to enhanced inhibition of KRAS-dependent signaling or overcoming adaptive feedback mechanisms. This opens an opportunity to investigate combinations of KRASG12D inhibitors with other inhibitors of MAPK and PI3K pathways. Here we report a data for 40-point combination dose response matrix combining VRTX153, a novel and highly selective inhibitor of KRASG12D with Alpelisib (a p110α inhibitor) and an EGFR inhibitor using MTT assay. Effect on downstream markers such as pERK, pEGFR and pAKT is being investigated. In vivo pharmacological effect of these agents will be investigated in the due course of development. Citation Format: Prashant Kashinath Bhavar, Uday Kumar Surampudi, Adilakshmi Gandham, Partha Pratim Sarma. Targeting EGFR and PI3K pathways with KRASG12D inhibitor overcomes oncogenic dependence in pancreatic cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1076.

oncology